(DOC) UPE -Luân | Tanluan Huynh

Trang chủ » đóng Rắn Upe » (DOC) UPE -Luân | Tanluan Huynh

Có thể bạn quan tâm

Đánh Giá Kết Quả Sống Thêm Và Tác Dụng Không Mong Muốn Của Phác Đồ Bước Hai Irinotecan Trên Bệnh Nhân Ung Thư Phổi Tế Bào Nhỏ Giai Đoạn Lan TrànHưng Đỗ

Tạp chí Y học Việt Nam, 2023

Assessing progression-free survival and adverse events of second-line irinotecan chemotherapy in patients with extensive small-cell lung cancer at the K Hospital. Patients and method: Retrospective and prospective analysis of 32 extensive small-cell lung cancer patients treated with second-line irinotecan chemotherapy at the K Hospital from January 2018 to November 2022. Results: Mean progression-free survival (PFS) was 13.9±2.3 weeks. The most common adverse events (AEs) were hematologic AEs with neutropenia grades 3-4 (18.8%) and leucopenia grades 3-4 (15.6%). Diarrhea and nausea grades 3-4 were reported in minority of patients. Conclusion: Second-line of irinotecan chemotherapy had a good progression-free survival and the profile of toxicity was acceptable.

downloadDownload free PDFView PDFchevron_right

Từ khóa » đóng Rắn Upe